Priority Date: 16.01.12 (JP 20120006354)

MARKER PEPTIDE FOR DETERMINING RISK OF DEVELOPING METABOLIC SYNDROME AND USE THEREOF

  • Application ID: EP12866020
  • Status: EXAMINATION IN PROGRESS

Attorney

Employment test 51 - 200 employees
Company dna hoffmann eitle
operating since 1892
Headquarter in Munich and 4 offices
active in Legal Services and IP Portfolio Processing

Specialization

This patent has the IPC combination C07, C12, and G01 is specialized in the combination C07, C12, and G01. We found, that TransMIT GmbH, Kailuweit & Uhlemann, dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB, Kilburn & Strode LLP, Potter Clarkson LLP and 62 others are specialized in all of these IPC classes. For a similar patent, they might be a good choice.

Timeline

  • 16.01.2012 - Priority Date (JP 20120006354)
  • 25.07.2013 - Publication A1 (WO2013108561)
  • 26.11.2014 - Publication A1 (EP2805966)